Research programme: signal regulatory protein alpha x anti-CCC based therapeutics - HanchorBio
Latest Information Update: 28 Aug 2023
At a glance
- Originator HanchorBio
- Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action CD47 antigen inhibitors; Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 20 Jul 2023 Early research in Cancer in Taiwan (unspecified route) (HanchorBio pipeline, July 2023)